Pfizer CEO Discusses Progress on Weight-Loss Drugs

Written by Emily J. Thompson, Senior Investment Analyst

Source: Yahoo Finance

Updated: 1d ago

0mins

PFE+2.76%

Should l Buy PFE?

Source: Yahoo Finance

Weight-Loss Drug Development: Pfizer's GLP-1 weight-loss drug is targeted for market entry in 2028, with CEO Albert Bourla stating that the 9.6 mg high dose will be tested in phase three trials, predicting that weight loss at week 28 will surpass competitors.
Market Demand Analysis: Despite the popularity of GLP-1 medications, 40% to 50% of patients discontinue use within a year, particularly among those over 65, indicating a significant unmet medical need in the market.
Diverse Product Portfolio: Pfizer's portfolio includes monthly and quarterly injectable medications that combine GLP-1 and Amylin, aiming to enhance patient tolerability and convenience, thereby strengthening its competitive position.
Strategic Positioning: Pfizer plans to leverage its diverse injectable and oral drug combinations, utilizing the company's robust R&D capabilities to aim for a leading role in the rapidly growing weight-loss drug market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.

PFE

$27.22+Infinity%1D

Analyst Views on PFE

Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Analyst Rating

5 Buy

11 Hold

0 Sell

Moderate Buy

Current: 26.490

Low

24.00

Averages

28.56

High

35.00

Current: 26.490

Low

24.00

Averages

28.56

High

35.00

Cantor Fitzgerald

Neutral

maintain

$24 -> $27

2026-01-27

Reason

Cantor Fitzgerald

Price Target

$24 -> $27

AI Analysis

2026-01-27

maintain

Neutral

Reason

Cantor Fitzgerald raised the firm's price target on Pfizer to $27 from $24 and keeps a Neutral rating on the shares. With 2026 guidance already issued and only modest beat-and-raise potential expected, the earnings call is likely to be quiet, with focus shifting to the timing and framing of VESPER-3 obesity data, the analyst tells investors in a research note Incremental updates on the Lyme disease vaccine, mevro in prostate cancer, or sigvotatug vedotin in non-small cell lung cancer are expected to be more influential than the 4Q25 results, the firm says.

UBS

Neutral

initiated

$25

2026-01-06

Reason

UBS

Price Target

$25

2026-01-06

initiated

Neutral

Reason

UBS assumed coverage of Pfizer with a Neutral rating and $25 price target. The firm noted a backdrop of continued revenue uncertainty with $15B-$20B in revenues from key drugs losing patient exclusivity over the coming roughly three years. Though the firm is positive on the recent MTSR obesity deal, Pfizer needs to do more to offset 2028 LOE risk, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PFE

Unlock Now

About PFE

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

PFIZER - FDA SCHEDULES PDUFA DECISION DATE FOR HYMPAVZI IN SECOND QUARTER OF 2026

2 days agomoomoo

FDA Action Date: The FDA has set an action date for the approval of HYMPAZIV, which is scheduled for the second quarter of 2026.
HYMPAZIV Overview: HYMPAZIV is a medication developed by Pfizer, indicating ongoing advancements in pharmaceutical treatments.

FDA Approves Priority Review for HYMPAVZI® (Marstacimab) SBLA to Address Significant Medical Needs in Hemophilia A and B Patients

2 days agomoomoo

FDA Grants Priority Review: The FDA has granted priority review for the treatment of two patient populations with significant medical needs using HYM-PAVZ® (MARS-TACIMAB).
Focus on Hemophilia A: The review specifically targets patients with Hemophilia A, indicating a critical advancement in treatment options for this condition.

Pfizer Launches TrumpRx Program to Reduce Drug Costs

2 days agoNewsfilter

Significant Drug Price Reductions: Pfizer's launch of the TrumpRx program offers substantial discounts on over 30 medications, with savings up to 85% and an average of 50%, aimed at alleviating the financial burden on American patients and enhancing their access to healthcare.
Historic Agreement Support: This initiative is part of Pfizer's landmark Most Favored Nation agreement with the Trump administration, designed to lower prescription drug prices for U.S. patients while reinforcing America's leadership in global pharmaceutical innovation.
Broad Patient Benefits: More than 100 million patients will benefit from discounted access to these medications, which treat a variety of conditions including migraines, rheumatoid arthritis, and menopause, significantly improving their quality of life and healthcare options.
Enhanced Partnerships: Pfizer's collaboration with GoodRx allows patients to use coupons at nearly any U.S. pharmacy or opt for home delivery services, further increasing flexibility and convenience in accessing medications.

Healthcare Sector Earnings Overview

1 day agoseekingalpha

Earnings Progress: As of February 6, 23 healthcare companies reported earnings, bringing the sector's overall reporting progress to 38%, indicating stability in industry performance and heightened investor interest.
Pfizer Earnings Highlight: Pfizer (PFE) posted a strong Q4 with revenue of $17.6 billion, exceeding expectations; however, its shares fell due to projected revenue contraction in 2026, reflecting market concerns about future growth.
AbbVie Outperformance: AbbVie (ABBV) reported revenue of $16.62 billion and earnings per share of $2.71, surpassing Wall Street forecasts, driven by strong performance from its flagship product Humira, with a projected total sales growth of 9.5% for the year, boosting market confidence.
Merck's Dismal Outlook: Merck (MERK) reported a solid Q4 with revenue of $16.4 billion and EPS of $2.04, both beating expectations; however, its 2026 outlook fell short of Wall Street estimates, leading to a decline in share price and reflecting cautious market sentiment regarding future growth.